• Login
    View Item 
    •   ResearchSpace Home
    • Caprisa (Centre for the Aids programme of research in South Africa)
    • Research papers (Caprisa)
    • View Item
    •   ResearchSpace Home
    • Caprisa (Centre for the Aids programme of research in South Africa)
    • Research papers (Caprisa)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Key issues in the clinical development and implementation of TB vaccines in South Africa.

    Thumbnail
    View/Open
    Journal article (445.1Kb)
    Date
    2012
    Author
    Rustomjee, R.
    Mcleod, R.
    Hanekom, W.
    Steel, G.
    Mahomed, H.
    Hawkridge, Anthony.
    Welte, A.
    Sinanovic, E.
    Loots, G.
    Grobler, Anna Christina.
    Mvusi, L.
    Gray, Glenda E.
    Hesseling, A.
    Ginsberg, A.
    Lienhardt, C.
    Shea, J.
    Tong, X.
    Lockhart, S.
    Churchyard, Gavin J.
    Metadata
    Show full item record
    Abstract
    Significant progress has been made in advancing the development pipeline for a new and more effective TB vaccine with some candidate vaccines now in late stage clinical evaluation. However, progress has been hampered by an incomplete understanding of the components of a protective immune response and limited animal models, rendering the field unable to reliably predict vaccine efficacy earlier in preclinical development, including by evaluation in animal models, and limiting the predictive utility of comparing immunogenic effects across vaccine candidates in phase I/II studies. Consequently, new candidate vaccines have to be evaluated for efficacy in large-scale phase II/III trials using clinical endpoints. Apart from the technical challenges of characterising TB incidence in target populations at high risk of acquiring TB disease and standardising case definitions in order to improve both the sensitivity and more importantly the specificity of trial endpoints, there is an urgency in expanding and supporting the considerable trial infrastructure that will be required to evaluate and ultimately license a new TB vaccine. In the longer term, implementation strategies are dependent on what policy makers most value. Economic analyses will be essential to guide policy and implementation. This paper outlines the gaps and challenges and identifies solutions for effectively developing and efficiently introducing a new TB vaccine.
    URI
    http://dx.doi.org/10.1016/j.tube.2012.05.001
    http://hdl.handle.net/10413/9239
    Collections
    • Research papers (Caprisa) [447]

    DSpace software copyright © 2002-2013  Duraspace
    Contact Us | Send Feedback
    Theme by 
    @mire NV
     

     

    Browse

    All of ResearchSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsAdvisorsTypeThis CollectionBy Issue DateAuthorsTitlesSubjectsAdvisorsType

    My Account

    LoginRegister

    DSpace software copyright © 2002-2013  Duraspace
    Contact Us | Send Feedback
    Theme by 
    @mire NV